Tebotelimab

Drug identity checked against registry records

Also recorded as MGD013

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck CancerNCT04634825MacroGenicsPhase 2Terminated2022-07-29Actual
Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ CancerNCT04082364MacroGenicsPhase 2, Phase 3Completed2024-01-15Actual

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.